Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Novo Nordisk Pharmaceuticals Co. Ltd
EIR
•Novo Nordisk Pharmaceuticals Co. Ltd•November 2, 2017

Novo Nordisk Pharmaceuticals Co. Ltd – FDA EIR, Nov 2, 2017

Record Details

A routine FDA inspection of Novo Nordisk Pharmaceuticals Co. Ltd. in Tianjin, China, was conducted from October 30 to November 2, 2017. The inspection focused on the manufacturing and quality systems for their NovoPen Echo insulin delivery pens, a Class 2 medical device cleared through 510(k) processes. The scope included Management Controls, Corrective and Preventive Actions (CAPA), Production and Process Controls (P&PC), and Design Controls. Notably, the inspection concluded with no 483 Inspectional Observations or discussion items, indicating full compliance with regulatory standards at the time of the audit. This positive outcome followed a previous FDA inspection in 2009 that also yielded no observations. Despite the compliant inspection, the report referenced an earlier voluntary recall, initiated by the parent company Novo Nordisk A/S on July 5, 2017, concerning potential cracking of NovoPen Echo Cartridge Holders. This issue, related to contact with cleaning agents, posed a risk of reduced insulin dose delivery, with the cartridge holders manufactured at the Tianjin site. While this pre-existing recall was noted, it did not result in new violations during this specific inspection. The facility demonstrated adherence to various procedures, including Unique Device Identification (UDI) labeling requirements. Consequently, no new regulatory actions were required from this FDA inspection.

Company
Novo Nordisk Pharmaceuticals Co. Ltd
Inspection date
November 2, 2017
Product type
Tobacco
Office
Office of Medical Products and Tobacco Operations
People
  • Bjarke Dupont Jorgensen (company_representative)
  • Nathalie Helix-Nielsen (company_representative)
  • Robert Fischer (company_representative)
  • WenHe Wang (company_representative)
  • Henrik Friese (company_representative)
View Company Profile

ID · c53f9c2c-5d4a-4985-b549-eb2619f1bf5c

Violation Codes3
21 CFR 21121 CFR 820.10021 CFR 820.30

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Novo Nordisk Pharmaceuticals Co. Ltd
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.